Nanotherapeutics Receives U.S. Department of Defense Contract for Clinical Trial to Treat Dehisced Wounds with NanoDOX(R) Hydrogel

ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, Inc. announced that it has been awarded a contract by the U.S. Department of Defense (DOD) to support a clinical trial for treating dehisced surgical wounds with the Company’s NanoDOX® Hydrogel, a topical doxycycline hydrogel for chronic wounds. Nanotherapeutics is collaborating with Walter Reed Army Medical Center, the Henry Jackson Foundation, and the Armed Forces Institute of Pathology to conduct the trial. Funds were made available from the DOD 2009 Congressional appropriation for the Accelerating Treatment for Trauma Wounds.